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Background: Secondary brain injury accounts for a major part of the morbidity and mortality in patients with
spontaneous aneurysmal subarachnoid hemorrhage (SAH), but the pathogenesis and pathophysiology remain
controversial. MicroRNAs (miRNAs) are important posttranscriptional regulators of complementary mRNA targets
and have been implicated in the pathophysiology of other types of acute brain injury. Cerebral microdialysis is a
promising tool to investigate these mechanisms. We hypothesized that miRNAs would be present in human
cerebral microdialysate.
Methods: RNA was extracted and miRNA profiles were established using high throughput real-time quantification
PCR on the following material: 1) Microdialysate sampled in vitro from A) a solution of total RNA extracted from
human brain, B) cerebrospinal fluid (CSF) from a neurologically healthy patient, and C) a patient with SAH; and 2)
cerebral microdialysate and CSF sampled in vivo from two patients with SAH. MiRNAs were categorized according
to their relative recovery (RR) and a pathway analysis was performed for miRNAs exhibiting a high RR in vivo.
Results: Seventy-one of the 160 miRNAs detected in CSF were also found in in vivo microdialysate from SAH
patients. Furthermore specific miRNAs consistently exhibited either a high or low RR in both in vitro and in vivo
microdialysate. Analysis of repeatability showed lower analytical variation in microdialysate than in CSF.
Conclusions: MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a
high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the
investigation of secondary brain injury in neurocritical conditions.Background
Secondary brain injury accounts for a major part of the
morbidity and mortality in patients with spontaneous
aneurysmal subarachnoid hemorrhage (SAH) [1]. How-
ever, the cellular mechanisms leading to this complication
are incompletely understood. Cerebral microdialysis, in
which a catheter lined by a semipermeable membrane is
perfused in order to sample fluid containing substances
from the cerebral interstitial space, is a promising tool to
investigate these mechanisms. Even so, the substances
measured in the clinical setting today are largely limited* Correspondence: bache@dadlnet.dk
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unless otherwise stated.to products of metabolism, such as glucose, lactate and
pyruvate [2,3].
MicroRNAs (miRNAs) are a group of 22 nucleotides
long, non-coding RNA molecules involved in posttran-
scriptional regulation of complementary mRNA targets
[4]. MiRNAs are well conserved in animals and are
highly tissue specific. They act intracellularly, are trans-
ported outside the cells in exosomes and may exist in
stable forms in body fluids [5]. Specific miRNAs are im-
plicated experimentally in neuronal apoptosis following
acute cerebral ischemia [6,7] intracerebral hemorrhage
[8] and are associated clinically with the severity of trau-
matic brain injury [9]. Measuring the interstitial concen-
tration of specific miRNAs may provide valuable
information on tissue function. We hypothesized that
miRNAs are present in human cerebral interstitial fluid,
are consistently filtered through the membrane of a cere-
bral microdialysis catheter, and hence, can also be detectedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ation. Thus, we aimed to develop and validate a method to
measure miRNA expression in cerebral microdialysate.
Methods
The protocol for this study was approved by the Danish
Regional Scientific Ethics Committee of the Capital
Region # H-3-2013-009 and registered on clinicaltrials.gov
# NCT01791257. According to Danish law, the samples
described below were obtained following informed con-
sent by either the patient or by their next of kin and their
general practitioner.
Samples
In order to compare RNA in undialyzed samples to sam-
ples that had undergone microdialysis, human cerebral
RNA, CSF and cerebral microdialysate was obtained and
processed as follows:
1. Samples for in vitro studies:Figure 1 Materials and methods. A: Setup for in vitro microdialysis. 1,
cerebrospinal fluid sample; 2, identical aliquots of the cerebrospinal
fluid; 3, two microdialysis catheters with a membrane length of 10 mm
and a 20 kDa cut-off; 4, perfusion pumps; 5, vials gathering samples of
microdialysis fluid. B: Computed tomography scan from SAH patient 3.
1, a microdialysis catheter placed in the left frontal lobe; 2, part of the
external drain passing through the brain.A. Total RNA extracted from human brain
(Clontech Laboratories, Inc., California, USA)
was stored at −80°C until use. Upon thawing,
RNA was reconstituted in “CNS perfusion fluid”
(MDialysis, Stockholm, Sweden) for a final
volume of 3 ml and concentration of 21 μg/ml
and divided into three aliquots. Samples
underwent in vitro microdialysis as described
below, using a catheter pore size of 20 or
100 kDa, or no microdialysis. The resulting
samples were named “RNA MD20”, “RNA MD
100”, and “RNA REF”.
B. CSF (2 ml) was aspirated using a 27G pencil
point spinal needle prior to injection of local
anesthetic in a neurologically healthy patient
undergoing spinal anesthesia (hereafter referred
to as a “healthy control patient”). The CSF was
spun at 500 g for 10 minutes; the supernatant was
stored at −80°C until use. Upon thawing and
division into two aliquots, one sample underwent
in vitro microdialysis as described below using a
catheter pore size of 100 kDa, whereas the other
sample was left undialyzed. The resulting samples
were named “H MD100” and “H REF”.
C. CSF (5 ml) was sampled from the external
ventricular drainage system placed in a patient
with SAH (patient 1) on day 6 after ictus. The
CSF was spun at 500 g for 10 minutes; the
supernatant was stored at -80°C until use. Upon
thawing and division into five aliquots, four of
these underwent in vitro microdialysis as described
below, using four identical catheters with a pore
size of 20 kDa, resulting in samples named “SAH1
MD20A through D”, whereas the remaining aliquotserved as four undialyzed reference samples,
named “SAH1 REFA through D”.
Figure 1A depicts the in vitro study setup.
2. CSF and microdialysate samples for in vivo study:
In two patients with SAH treated with external
ventricular drainage and undergoing bedside
microdialysis on clinical indications (patients 2 and
3), CSF from the drainage system as well as
microdialysate from an intracerebral microdialysis
catheter (Figure 1B) containing a 20 kDa membrane
were collected on Day 3 and 9. This resulted in eight
samples named “SAH2D3 MD20”, “SAH3D3
MD20”, “SAH2D9 MD20”, “SAH3D9 MD20”,
“SAH2D3 REF”, “SAH3D3 REF”, “SAH2D9 REF”,
and “SAH3D9 REF”.
Details regarding in vitro and in vivo samples are
shown in Table 1. CSF samples were spun at 500 g for
Table 1 Schematic overview of pre-analytical and analytical setup






1 RNA MD20 Human brain, total RNA In vitro 20 kDa CNS 377
2 RNA MD100 Human brain, total RNA In vitro 100 kDa HA 3.5% 377
3 RNA REF Human brain, total RNA None NA NA 377
4 H MD100 Healthy human, LP-CSF In vitro 100 kDa HA 3.5% 377
5 H REF Healthy human, LP-CSF None NA NA 377
6 SAH1 MD20A SAH patient 1, EVD-CSF In vitro 20 kDa CNS 754
7 SAH1 MD20B SAH patient 1, EVD-CSF In vitro 20 kDa CNS 754
8 SAH1 MD20C SAH patient 1, EVD-CSF In vitro 20 kDa CNS 754
9 SAH1 MD20D SAH patient 1, EVD-CSF In vitro 20 kDa CNS 754
10 SAH1 REFA SAH patient 1, EVD-CSF None NA NA 754
11 SAH1 REFB SAH patient 1, EVD-CSF None NA NA 754
12 SAH1 REFC SAH patient 1, EVD-CSF None NA NA 754
13 SAH1 REFD SAH patient 1, EVD-CSF None NA NA 754
14 SAH2D3 MD20 SAH patient 2, in vivo MD, day 3 In vivo 20 kDa CNS 377
15 SAH3D3 MD20 SAH patient 3, in vivo MD, day 3 In vivo 20 kDa CNS 377
16 SAH2D9 MD20 SAH patient 2, in vivo MD, day 9 In vivo 20 kDa CNS 377
17 SAH3D9 MD20 SAH patient 3, in vivo MD, day 9 In vivo 20 kDa CNS 377
18 SAH2D3 REF SAH patient 2, EVD-CSF, day 3 None NA NA 377
19 SAH3D3 REF SAH patient 3, EVD-CSF, day 3 None NA NA 377
20 SAH2D9 REF SAH patient 2, EVD-CSF, day 9 None NA NA 377
21 SAH3D9 REF SAH patient 3, EVD-CSF, day 9 None NA NA 377
qPCR, real-time polymerase chain reaction; miRNA, microRNA; MD, microdialysis; CNS, “Central nervous system perfusion fluid” (Mdialysis); HA, human albumin
(CLS Behring); ref, reference; NA, not applied; LP-CSF, cerebrospinal fluid obtained by lumbar puncture; SAH, spontaneous aneurysmal subarachnoid hemorrhage;
EVD-CSF = cerebrospinal fluid obtained from external ventricular drain.
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use. Microdialysate was stored at -80°C until use.
Microdialysis
In vivo and in vitro microdialysis was carried out using
catheters (MDialysis, Stockholm, Sweden) with membrane
lengths of 10 mm and cut-off values of either 20 kDa or
100 kDa as outlined above and in Table 1. Catheters were
perfused at 0.3 μl min−1 with a CMA106 Microdialysis
Pump (MDialysis) using “CNS perfusion fluid” (MDialysis)
for 20 kDa membranes; for 100 kDa membranes, human
albumin (3.5%; CLS Behring, Copenhagen, Denmark) was
chosen because we observed fluid leakage across the
100 kDa membrane using “CNS perfusion fluid” as re-
ported by others [10]. Vials for sampling were replaced
every two hours, for a resulting volume of 36 μl per vial;
for subsequent RNA isolation, no in vivo vials sampled
within two hours of catheter insertion were used, the con-
tent of eight successive vials (288 μl) were pooled for each
sample, and 200 μl was transferred for further processing
as described below.
The temperature for all in vitro procedures was set at
37°C to resemble in vivo microdialysis. Undialyzedreference samples were kept at 37°C for two hours and
stored at -80°C until use.
RNA isolation
Total RNA was isolated from 200 μl of each sample
according to the manufacturer’s protocol (Total RNA
isolation kit, Appendix B, Norgen Biotek, Thorold,
Canada), including the addition of beta-mercaptoethanol
to the lysis solution.
Real-time quantification
For each sample, a fixed volume of 6 μl eluted RNA
sample was mixed on ice with 9 μl of a reverse transcrip-
tion reaction containing 1.6 μl of 10X RT buffer, 1.8 μl
of MgCl2, 0.2 μl of RNase-inhibitor (20 U/μl), 0.4 μl of
dNTPs with dTTP (100 mM), 3.0 μl of Multiscribe Re-
verse Transcriptase (50U/μl), 1.6 μl of Megaplex RT
primers (x10) and 0.4 μl of nuclease free water. Reverse
transcription was performed using 40 cycles of 16°C,
2 min; 42°C, 1 min and 50°C, 1 sec followed by 85°C for
5 min and hold at 4°C. For each sample, a preamplifica-
tion reaction comprising 62.5 μl of TaqMan PreAmp
Master Mix (2X), 12.5 μl of Megaplex PreAmp Primers
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product were mixed on ice. After 10 min at 95°C, 2 min
at 55°C and 2 min at 72°C the cDNA was subjected to
12 cycles of 15 sec at 95°C and 4 min at 60°C followed
by 10 min at 99,9°C and hold at 4°C. The preamplified
product was diluted with 375 μl of 0.1 TE buffer. For
each sample, 450 μl of diluted preamplified product was
mixed on ice with 450 μl of TaqMan Fast Advanced
Master Mix and 800 μl loaded on a TaqMan Human
MicroRNA Array Card. qRT-PCR was performed using
the Viia 7 real-time PCR system (Applied Biosystems,
Foster City, CA). Samples 6–13 were screened for 754
specific miRNAs using Human Pools A v.2.1 and B v.3.0.
The remaining samples were screened for 377 specific
miRNAs using Human Pools A v.2.1. Reagents and array
cards were all purchased from Invitrogen, Carlsbad, CA.
Normalization & statistical analysis
Cycle threshold was set to 0.1 and baseline between 3
and 15 for all targets. Cycle quantification (Cq) values
correlate inversely with concentration. A Cq value >32
were considered below the detection limit and were
discarded and the mean normalization strategy [11]
was applied. To compare measurement variability in
microdialysate and CSF, SDs were compared using the
paired Student’s t test. P < 0.05 was considered significant.
MiRNAs were categorized according to their relative
recovery (RR) in microdialysate as exhibiting a “high” or
“low” RR according to the criteria described in Table 2;
miRNAs, for which this characterization was not pos-
sible, were classified as having an “indeterminate” RR.
Please refer to Table 2 for a detailed description of the
criteria for categorization.
MiRNA target pathway analysis
MiRNAs exhibiting a high RR in vivo were uploaded to
the Ingenuity Pathway Analysis software (Qiagen, Venlo,
Holland) and a search of putative mRNA targets was
performed which was limited to “experimentally ob-
served”. Target mRNAs were subsequently employed inTable 2 Criteria for categorization
Groups Inclusion criteria for each specific miRNA
High RR in vitro Cqmean CSF – Cqmean MD < ±2 and in vit
and SDMD both < 1
Low RR in vitro Cqmean MD - Cqmean CSF > 4 and in vitro
Indetermined RR Criteria not fulfilled
Not present Not detected in any samples
Criteria for categorization of 754 screened miRNAs according to their relative recov
RR, relative recovery; Cqmean CSF, mean cycle quantification of the specific miRNA in
miRNA in sample 6-9, Table 1; SDCSF, standard deviation of cycle quantification of th
quantification of the specific miRNA in sample 6-9, Table 1.a gene set enrichment analysis in the C2 Reactome Mo-
lecular Signature Database v4.0 (www.broadinstitute.org).
A similar analysis was performed with a gene set of
mRNAs that have been reported by others to be differen-
tially expressed between the brain tissue from the perihe-
matomal region and the contralateral region from patients
suffering from intracerebral hemorrhage [12].
Results
MiRNA profiles of CSF and microdialysate
In the sample of total RNA extracted from human brain
tissue, 205 out of 377 tested miRNAs (60%) were de-
tected in the undialyzed reference sample; of these 205
miRNAs, 171 (83%) were detected after in vitro micro-
dialysis using a membrane cutoff of 20 kDa, and 84
(41%) were detected after microdialysis using a 100 kDa
membrane.
In the healthy control patient, 114 of 377 tested miR-
NAs (34%) were detected in undialyzed CSF; of these
114 miRNAs, 71 (62%) were detected after in vitro mi-
crodialysis using a 100 kDa membrane.
In the three patients with SAH, samples from patient
1 were screened for 754 specific miRNAs, whereas sam-
ples from patients 2 and 3 were screened for the pres-
ence of 377 miRNAs. In patient 1, 203 miRNAs were
detected in all four identical samples of CSF, of which
112 (55%) were detected in all four corresponding
microdialysate samples obtained in vitro. In patients 2
and 3, 160 miRNAs were detected in all four samples of
CSF, and 71 (44%) of these were detected in all four
samples of microdialysate obtained in vivo. Conversely,
all miRNAs identified in all four in vivo samples of
microdialysate were also identified in in vivo CSF. All
mean normalized Cq values of specific miRNAs can be
found in Additional file 1.
Selective passage of microdialysis membrane
The microdialysate relative recovery (RR) of different
miRNAs varied considerably in the in vitro studies.
However, the RR of each specific miRNA was consistentBased on samples miRNA targets
ro SDCSF 6-13 63
6-13




ery in microdialysate from a catheter with a membrane cut-off value of 20 kDa.
sample 10-13, Table 1; Cqmean MD, mean cycle quantification of the specific
e specific miRNA in sample 10-13, Table 1; SDMD, standard deviation of cycle
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screened, 63 were categorized as exhibiting a high RR,
53 as exhibiting a low RR, and 173 as exhibiting an inde-
terminate RR. The 465 remaining miRNAs were not
identified in the reference material and therefore could
not be evaluated. These characteristic abilities to pass
through the membrane were reproduced in the in vivo
studies. Figures 2 and 3 show Cq values of representative
miRNAs from the group with a high RR and the one
with a low RR and illustrates the reproducibility from
in vitro to in vivo studies. The complete distribution
of all 754 miRNAs in the four groups is shown in
Additional file 2.
Repeatability
In order to investigate analytical variation, we compared
standard deviations of Cq values in microdialysate and
CSF from patient 1 (SAH1 MD20A through D compared
to samples SAH1 REFA through D, Table 1). Since miR-
NAs at low concentrations increase analytical variation
in qRT-PCR markedly, including miRNAs with a low or
indeterminate RR would lead to an overestimation of
the analytical variation contributed by microdialysate.
Therefore, analysis focused on the group of 63 miR-
NAs showing a high RR; the average SD of Cq values in
microdialysate was lower than that of CSF (SD for
microdialysate, 0.37 (95% CI, 0.33-0.42) vs. SD for CSF,
0.46 (95% CI, 0.41-0.51) (p = 0.011).
MiRNA target pathway analysis
In order to obtain an overview of the possible biological
significance of the 31 miRNAs exhibiting a high RR in
microdialysate obtained in vivo, we performed a pathway
analysis of putative target mRNAs. Transcripts were
matched to the C2 Reactome in the Molecular Signature
Database v4.0, and the 50 most significantly related reac-
tomes (FDR q-value ≤ 1.02 × 10−5) are listed in Additional
file 3. Comparing these results to the 50 most significantly
related reactomes (FDR q-value ≤ 4.64 × 10−3) from a
similar pathway analysis, based on a gene set of mRNAs
differentially expressed between the brain tissue from the
perihematomal region and the contralateral region from
patients suffering from intracerebral hemorrhage, revealed
an overlap of 13 reactomes (Additional file 3).
Discussion
We have shown that miRNAs, important regulators of
cell function, can be detected in human cerebral micro-
dialysate sampled in vivo. Our findings have three main
implications. First, this method offers a new approach to
test hypotheses related to the presence, regulation and
roles of miRNAs in the brain of neurocritically ill pa-
tients. Secondly, in vivo microdialysis for the study of
miRNA is not limited to brain tissue, but could likely beapplied to many tissues. Finally, the membrane of a
microdialysis catheter resembles a semi-permeable mem-
brane, and the results provide information on the
much-debated topic of the size and characteristics of
the proposed forms of miRNA which may prevent their
degradation by RNases [13].
Besides showing the presence of miRNAs in cerebral
microdialysis fluid sampled in vivo, the in vitro part of
this study demonstrated that 63 out of 754 screened
miRNAs show a high RR when using a 20 kDa microdi-
alysis membrane. Of these 63 miRNAs, 34 were screened
in the in vivo samples, and for 26 of these, a high RR
was confirmed using the same criteria as for the in vitro
study (Figure 2 - bottom). Of the remaining eight miR-
NAs, seven miRNAs came very close to meeting the cri-
teria for a high RR; only one miRNA showed a markedly
different expression pattern and variation. The reason
for this outlying result is unknown, but could be due to
both analytical imprecision or biological variation within
samples. Nevertheless, the in vivo confirmation of the
in vitro results shows consistency in the ability of each
given miRNA to filter through the microdialysis mem-
brane. Therefore, we recommend that future studies
may include 62 of the 63 miRNAs meeting the criteria
for a high RR, since their filtration fraction may be as-
sumed to be stable as well.
The cut-offs for a given miRNA to be placed in the
“high RR” group, an SD < 1 Cq and a microdialysate to
CSF difference of < 2 Cq, was a compromise between
increasing specificity by lowering both cut-offs and the
challenge that each SD represents the qRT-PCR of one
well from each of four array cards in order to allow for a
wide miRNA-screening. This approach, however, means
that the analytical variation cannot be reduced by run-
ning multiplicates (e.g.triplicates) of each miRNA. In our
opinion, this may be a suitable approach when studying
limited amounts of specific miRNAs of interest.
In order to compare samples obtained from different
patients, at different time points, we estimated the analyt-
ical variation. For the 63 miRNAs showing a high RR, the
average variability of expression values was significantly
lower in microdialysate than in CSF. One explanation
could be that microdialysis removes larger molecules,
which interferes with downstream analysis or parts thereof
(e.g. RNA extraction) in the undialyzed control samples.
Nevertheless, the observation that microdialysis may
not decrease, but in fact seems to increase, reproduci-
bility of qRT-PCR, is important. Thus, microdialysis
may provide a more accurate method than simple CSF
sampling to monitor changes in cerebral miRNA ex-
pression over time and between patients and patient
groups.
The above findings indicate that it may be possible to
quantify the cerebral interstitial concentration of at least
Figure 2 High relative recovery of miRNA. Mean normalized cycle quantification (Cq) for miRNAs showing a high relative recovery during
microdialysis in vitro (1A, 1B, 1C) and in vivo (2). 1A: Cq values of miRNAs after in vitro microdialysis on total RNA from human brain. Dark grey
column, 20 kDa membrane; grey column, 100 kDa membrane; light grey column, undialyzed reference sample. 1B: Cq values of miRNAs after
in vitro microdialysis on CSF from a neurologically healthy patient. Dark grey column, 100 kDa membrane; light grey column, undialyzed
reference sample. 1C: Mean Cq values of miRNAs after in vitro microdialysis on CSF obtained by lumbar puncture in a neurologically healthy
patient. Dark grey column, 20 kDa membrane; light grey column, undialyzed reference sample. Error bars show SD (N of identical aliquots = 4). 2:
Mean Cq values of miRNAs in in vivo microdialysate and CSF obtained from patients with subarachnoid hemorrhage. Dark grey column, in vivo
microdialysate, 20 kDa membrane; light grey column, CSF, external ventricular drain. Error bars show SD (N of aliquots for each = 4). The four
samples of each material was taken from two different patients with SAH on Day 3 and 9.
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Additionally, some miRNAs with an indeterminate or
low RR appear to show acceptable measurement accur-
acy, though this would require additional studies.Finally, according to the experience in our laboratory,
miRNAs may be quantified from as little as 25 μl of
microdialysate, i.e. much less than used in this study,
with good reproducibility (data not shown), indicating
Figure 3 Low relative recovery of miRNA. Mean normalized cycle quantification (Cq) for miRNAs showing a low relative recovery during
microdialysis in vitro (1A, 1B, 1C) and in vivo (2). 1A: Cq values of miRNAs after in vitro microdialysis on total RNA from human brain. Dark grey
column, 20 kDa membrane; grey column, 100 kDa membrane; light grey column, undialyzed reference sample. 1B: Cq values of miRNAs after
in vitro microdialysis on CSF from a neurologically healthy patient. Dark grey column, 100 kDa membrane; light grey column, undialyzed
reference sample. 1C: Mean Cq values of miRNAs after in vitro microdialysis on CSF obtained by lumbar puncture in a neurologically healthy
patient. Dark grey column, 20 kDa membrane; light grey column, undialyzed reference sample. Error bars show SD (N of identical aliquots = 4). 2:
Mean Cq values of miRNAs in in vivo microdialysate and CSF obtained from patients with subarachnoid hemorrhage. Dark grey column, in vivo
microdialysate, 20 kDa membrane; light grey column, CSF. Error bars show SD (N of aliquots for each = 4). The four samples of each material was
taken from two different patients with SAH on Day 3 and 9.
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resolution are possible in a clinical setting.
To our knowledge, this is the first time that in vivo
microdialysis has been conducted in humans in order tosample miRNAs. For local changes in interstitial miRNA
levels to be of importance, they need to reflect the intra-
cellular levels. Accordingly, in vitro studies indicate that
an energy-dependent equilibrium exists between the
Bache et al. Journal of Translational Medicine  (2015) 13:149 Page 8 of 10intracellular and extracellular compartments regarding
miRNAs [14]. Furthermore, the miRNAs presented in
Table 3 have previously been implicated in cerebral is-
chemia or inflammation. For instance, up-regulation of
miR-29b in brain tissue following experimental transient
middle cerebral artery occlusion, was found to inhibit
Bcl2L2 gene expression resulting in increased neuronal
cell death. In addition, inhibition of miR-29b increased
Bcl2L2 gene expression and decreased neuronal cell
death, indicating that miR-29b may be an important me-
diator of an adverse outcome in cerebral ischaemia [7].
In the present study, miR-29b showed a high RR in cere-
bral microdialysate. We suggest that changes in miR-29b
may be monitored by microdialysis in humans in order
to test the hypothesis raised in the study described
above. Similarly, miR-34a and miR-155, which have been
implicated experimentally in traumatic brain injury
[15] and central nervous system inflammation follow-
ing cerebral ischemia [16], both exhibited a high RR
and therefore will be of great interest to monitor in
similar patients. More generally, we compared results
of pathway analyses of our data set of miRNAs exhibit-
ing a high RR in vivo and a data set from patients with
intracerebral hemorrhage. These analyses indicate that
miRNAs exhibiting a high RR in vivo, may be impli-
cated in the regulation of transcripts involved in
among others hemostasis; axon guidance; signaling by
nerve growth factor; adaptive immune system; plateletTable 3 Selected references reporting roles of miRNAs with a
MiRNA Author, year Design/model Tiss





in cortical neuronal cell cultures
from rats.
B: C




B: Microglia cell culture from mice B: C
Truettner et al, 2013 [15] Stretch injury, cortical neuron
cultures from rats
Cell




B: Microglial cell culture
from mice
B: C
Freilich et al, 2013 [19] LPS stimulation, microglial
cell cultures from mice pups
Cell
MCA =middle cerebral artery, CNS = central nervous system, LPS = lipopolysaccharidactivation, signaling and aggregation; following intra-
cerebral hemorrhage.
The array cards used for miRNA screening were not
designed to test specifically for miRNAs located in the
brain and thus included a large number of miRNAs de-
rived from other tissues. This is probably the reason for
the 465 undetectable miRNAs in CSF and microdialy-
sate. Regarding miRNAs detected solely in CSF and not
in microdialysate, the molecular weight of a miRNA is
around 6.5 kDa, but there is evidence that miRNAs
acquire their extracellular stability from association in
microvesicles / exosomes or by forming a ribonucleopro-
tein complex with Argonaute2, thus achieving protection
against degradation by RNases [13,14,17]. Microvesicles
have a diameter of 100–1000 nm, exosomes have a
diameter of 30–100 nm, and Argonaute2 alone has a
molecular weight of 96 kDa [17]. The microdialysis
membranes used in the present study allows molecules
with a size up to respectively 20 kDa and 100 kDa to pass
through. Thus, microvesicles, exosomes and Argonaute2-
bound miRNAs should not be able to pass through the
membrane. By using differential centrifugation and size-
exclusion chromatography, Arroyo et al. found miR-142-
3p, −146b, −150, −193a-5p, −744 and −886-3p to be pre-
dominantly vesicle bound and miR-15b, 30c, 32, −126,
and −191 to be at least in part vesicle-bound [13]. This is
in agreement with data from our study, in which these
miRNAs showed a low RR and none of the remaininghigh relative recovery during cerebral microdialysis
ue/material Relation of miRNA to acute cerebral injury
rain tissue 24 hours
r occlusion
Increased miR expression (A+B), repression of the
anti-apoptotic protein Bcl2L2, and thereby
neuronal cell death (B).
ell suspension Pre-treating neuronal cultures with miR-29b inhibitor
decreased neuronal cell death (B)
icroglia extracted
ivo after 3 days
MiR promotes CNS inflammation in microglia by
suppressing transcription of the twist2 gene and
thereby the anti-inflammatory gene cMaf.
ell suspension Induced by expression of p53.
suspension MiR promotes apoptosis by inhibiting translation
of the anti-apoptotic proteins Bcl2 and XIAP and
increasing expression of the apoptotic cytokine
Caspase 11.
icroglia extracted
ivo after 3 days
Increased miR expression (A) MiR promotes CNS
inflammation in microglia by suppressing the
anti-inflammatory gene cMaf in microglia (A+B)
ell suspension Normal cytokine induced expression of miR-155
is suppressed in p53-deficient microglia (B).
Following treatment with INF-γ, the normal
expression of IL-1α and IL-1β are suppressed in
miR-155 knock out microglia cell cultures (B).
suspension Increased miR expression after LPS and thereby
activation of several pro-inflammatory pathways.
e.
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group showing a high RR (Figures 2 and 3). Equally im-
portant, the above-mentioned vesicle-bound miRNA ap-
peared to pass through the membrane when present as
isolated RNA alone, i.e. without vesicle constituents or
proteins (Figure 3-1A and Additional file 1). Furthermore,
the observation that some miRNAs exhibit a high RR sug-
gests that they exist at least partly in the free form in CSF,
or that molecules smaller than Argonaute2 act as carriers
in this medium.
The study has limitations regarding design and leaves
room for further investigation. First of all, the in vitro
study incubation at 37°C lasted on average 7 hours lon-
ger for samples used for microdialysis than for its identi-
cal reference samples. MiRNAs are considered stable in
CSF at room temperature [18], but we cannot exclude
that a fraction of miRNAs in the sample of total RNA
from human brain, isolated from the constituents medi-
ating RNase resistance, was degraded during this incuba-
tion period. Still, this would tend to reduce, rather than
increase, the concentrations of miRNA in the in vitro
microdialysate.
Secondly, as miRNA-profiling is still resource demand-
ing, these studies are based on small sample sizes from
few patients. We chose this approach in order to validate
as many miRNAs as possible. Increasing reproducibility
by increasing sample size would either increase costs
significantly or we would have to measure only a few
miRNAs. Likewise, we chose only to validate the in vitro
data from screenings of 754 specific miRNAs with
screenings of the 377 most common miRNAs (Human
Pools A v.2.1) as the recovery results for these miRNAs
could be extrapolated to the 377 miRNAs that were
omitted (Human Pools B v.3.0).
Finally, we observed that miRNAs showed a higher RR
through the membrane with a cut-off value of 20 kDa than
with a cut-off value of 100 kDa. We speculate that the
human albumin solution used as perfusion fluid for the
microdialysis catheter, with a membrane cut-off value of
100 kDa, may have reduced the RR of miRNAs, either by
repelling them or by somehow contributing to their degrad-
ation. At any rate, we found no indication of an increased
RR of miRNA using a membrane with a cut-off value of
100 kDa which is why the remaining studies of miRNA in
microdialysis was done using the 20 kDa membrane.
Conclusions
We have identified a group of miRNAs that show a high
relative recovery during microdialysis both in vitro and
in a clinical setting. In the future, it may be relevant to
study local changes in specific miRNAs in relation to
brain tissue oxygen tension, cerebral metabolites and
continuous electroencephalography as well as the clin-
ical course of the patient.Additional files
Additional file 1: All normalized Cq values. These four spreadsheets
show normalized Cq values of all screened miRNAs from the in vitro
study of microdialysis in the total RNA solution (1A), cerebrospinal fluid
from a neurological healthy patient (1B), cerebrospinal fluid from a
subarachnoid hemorrhage patient (1C) and normalized Cq values of all
screened miRNAs from the in vivo study of microdialysis and
cerebrospinal fluid from two subarachnoid hemorrhage patients sampled
at day 3 and 9 (2A). Blanks represents a raw Cq value above 32.
Additional file 2: All microRNA grouped according to relative recovery
(RR). This spreadsheet contains the 63 miRNA showing a high RR (column B),
the 53 miRNA showing a low RR (column C), the 173 miRNA showing an
indetermined RR (column D) and the 465 miRNA not detected (column E).
Additional file 3: Pathway analysis of miRNAs exhibiting a high
relative recovery (RR) in vivo. The 50 most significantly related
reactomes, including p-values and FDR q-values, from two gene set
enrichment analyses in the C2 Reactome Molecular Signature Database
v4.0 (www.broadinstitute.org) using the two target mRNA data sets
derived as described below. Left side of table – A miRNA target filter analysis
of the 31 miRNAs exhibiting a high relative recovery in microdialysate
obtained in vivo. The analysis was conducted using the software Ingenuity
Pathway Analysis (Qiagen, Venlo, Holland), and the search was limited to
relationships that are “experimentally observed”. Right side of table - Gene
set of mRNAs that have been reported to be differentially expressed in
perihematomal tissue after spontaneous intracerebral haemoorhage [12]. RR,
relative recovery; #, number of genes in gene set; GO, genes in overlap.
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